Gilead Sciences Inc.
GILD, + 0.40%
announced Monday afternoon that it plans to ask the food and drug administration to approve an arthritis this year. Gilead, in collaboration with Galapagos NV
GLPG, + 1.17%
has tested a substance known as filgotinib for rheumatoid arthritis, and recent study results ate investors in March. In a press release on Monday, Gilead said it met the FDA to discuss these test results recently. "As a result of this discussion, a way forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 201[ads1]9," the release says.